June 12, 2014 - ZOLL LifeVest Wearable Defibrillator and Temperature Management Solutions to be Showcased at Cardiostim 2014

 

MEDIA CONTACT:  

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR AND TEMPERATURE MANAGEMENT SOLUTIONS TO BE SHOWCASED AT CARDIOSTIM 2014



June 12, 2014—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator along with sudden cardiac death (SCD) education and screening tools, and the Intravascular Temperature Management (IVTM™) system, in Booths A34 and A43 at Cardiostim 2014 from 18-21 June in Nice, France.

The LifeVest will be discussed during the following scientific sessions:

  • Ilan Goldenberg, MD, University of Rochester Medical Center, and Stefan Winter, MD, Vinzenz Hospital, will present a symposium entitled “One-year follow-up of WCD patients,” Thursday, 19 June, 9:00-10:30 a.m., Session #94, Room 3.4 Uranie Level 3 Les Muses.
  • Mijic Dejan, MD, Klinikum Lüdenscheid, will present “The Wearable Cardioverter Defibrillator (WCD): A Sparkling Light in the Temporary Black Box before ICD Implantation,” Thursday, 19 June, 2:00 p.m., Poster Session 136.
  • Anil-Martin Sinha, MD, Sana Klinikum Hof, will present “Wearable Cardioverter Defibrillator in Patients with High Risk for Life-Threatening Cardiac Arrhythmias,” Thursday, 19 June, 2:00 p.m., Poster Session 136.
  • Nicole Bianco, PhD, ZOLL, will present “Long-Term Use of the Wearable Cardioverter Defibrillator in ICD Explant Patients,” Thursday, 19 June, 2:00 p.m., Poster Session 136.

The LifeVest protects patients at risk for SCD. It is used for a wide range of patient conditions or situations, including following a recent myocardial infarction or coronary revascularization. One in five post-acute myocardial infarction (AMI) patients have been shown to be at high risk of dying after percutaneous coronary intervention (PCI).1 The majority of mortality in AMI patients post-PCI occurs in the first three months—one out of every 10 high-risk patients die, with about 60% of this mortality due to SCD.1,2 The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

ZOLL’s IVTM system offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use, and cost-effective control for both cooling and warming applications. The temperature management system provides a variety of catheter options depending upon the specific patient needs.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2014 ZOLL Medical Corporation. All rights reserved. IVTM, LifeVest, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.

1 Halkin, A et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC 2005;45:1397–1405.
2 Stone, G et al. Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients. http://www.theheart.org/article/1202823.do (April 2011).